- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06357533
Fase III, aberto, estudo de Dato-DXd de primeira linha em combinação com Rilvegostomig para NSCLC não escamoso avançado com alta expressão de PD-L1 (TC ≥ 50%) e sem alterações genômicas acionáveis (TROPION-Lung10)
Um estudo global de fase III, randomizado, aberto, de Datopotamabe Deruxtecano (Dato-DXd) em combinação com Rilvegostomig ou Monoterapia com Rilvegostomig versus Monoterapia com Pembrolizumabe para o tratamento de primeira linha de participantes com NSCLC não escamoso localmente avançado ou metastático com alta Expressão de PD-L1 (TC ≥ 50%) e sem alterações genômicas acionáveis (TROPION-Lung10)
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a Phase III, randomized, open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig monotherapy compared with Pembrolizumab monotherapy for the first-line treatment of participants with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: AstraZeneca Clinical Study Information Center
- Número de telefone: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Locais de estudo
-
-
-
Berlin, Alemanha, 10249
- Ainda não está recrutando
- Research Site
-
Bonn, Alemanha, 53113
- Recrutamento
- Research Site
-
Cologne, Alemanha, 50677
- Recrutamento
- Research Site
-
Düsseldorf, Alemanha, 40489
- Retirado
- Research Site
-
Essen, Alemanha, 45136
- Recrutamento
- Research Site
-
Freiburg im Breisgau, Alemanha, 79106
- Recrutamento
- Research Site
-
Gauting, Alemanha, 82131
- Recrutamento
- Research Site
-
Georgsmarienhütte, Alemanha, 49124
- Retirado
- Research Site
-
Gera, Alemanha, 07548
- Retirado
- Research Site
-
Gütersloh, Alemanha, 33332
- Retirado
- Research Site
-
Hamburg, Alemanha, 20251
- Recrutamento
- Research Site
-
Hamburg, Alemanha, 22087
- Recrutamento
- Research Site
-
Heidelberg, Alemanha, 69126
- Recrutamento
- Research Site
-
Kempten, Alemanha, 87439
- Suspenso
- Research Site
-
Kiel, Alemanha, 24116
- Ainda não está recrutando
- Research Site
-
Koblenz, Alemanha, 56068
- Suspenso
- Research Site
-
Ludwigsburg, Alemanha, 71640
- Retirado
- Research Site
-
München, Alemanha, 81925
- Recrutamento
- Research Site
-
Nuremberg, Alemanha, 90419
- Retirado
- Research Site
-
Potsdam, Alemanha, 14467
- Recrutamento
- Research Site
-
Ravensburg, Alemanha, 88212
- Recrutamento
- Research Site
-
-
-
-
-
Birtinya, Austrália, 4575
- Retirado
- Research Site
-
Blacktown, Austrália, 2148
- Retirado
- Research Site
-
Clayton, Austrália, 3168
- Recrutamento
- Research Site
-
Gosford, Austrália, 2250
- Recrutamento
- Research Site
-
Melbourne, Austrália, 3000
- Retirado
- Research Site
-
South Brisbane, Austrália, QL 4101
- Recrutamento
- Research Site
-
Wodonga, Austrália, 3690
- Recrutamento
- Research Site
-
-
-
-
-
Barretos, Brasil, 14784-400
- Recrutamento
- Research Site
-
Curitiba, Brasil, 80730-150
- Recrutamento
- Research Site
-
Florianópolis, Brasil, 88034-000
- Recrutamento
- Research Site
-
Ipatinga, Brasil, 35162-189
- Recrutamento
- Research Site
-
Natal, Brasil, 59075-740
- Recrutamento
- Research Site
-
Porto Alegre, Brasil, 91350-200
- Recrutamento
- Research Site
-
Rio de Janeiro, Brasil, 22211-230
- Recrutamento
- Research Site
-
Santa Maria, Brasil, 97015-450
- Recrutamento
- Research Site
-
São Paulo, Brasil, 01221-020
- Recrutamento
- Research Site
-
Taubaté, Brasil, 12030-200
- Recrutamento
- Research Site
-
-
-
-
-
Anderlecht, Bélgica, 1070
- Retirado
- Research Site
-
Bruges, Bélgica, 8000
- Recrutamento
- Research Site
-
Hasselt, Bélgica, 3500
- Recrutamento
- Research Site
-
La Louvière, Bélgica, 7100
- Recrutamento
- Research Site
-
Liège, Bélgica, 4000
- Recrutamento
- Research Site
-
-
-
-
-
Chicoutimi, Canadá, G7H 5H6
- Recrutamento
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, VSZ 4E6
- Recrutamento
- Research Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá, R3E 0V9
- Retirado
- Research Site
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canadá, A1B 3V6
- Recrutamento
- Research Site
-
-
Ontario
-
London, Ontario, Canadá, N6A 4L6
- Recrutamento
- Research Site
-
Newmarket, Ontario, Canadá, L3Y 2P9
- Retirado
- Research Site
-
Oshawa, Ontario, Canadá, L1G 2B9
- Recrutamento
- Research Site
-
Toronto, Ontario, Canadá, M4N 3M5
- Retirado
- Research Site
-
-
Quebec
-
Lévis, Quebec, Canadá, G6V 0B8
- Recrutamento
- Research Site
-
Montreal, Quebec, Canadá, H4J 1C5
- Recrutamento
- Research Site
-
Montreal, Quebec, Canadá, H3T 1E2
- Recrutamento
- Research Site
-
Montreal, Quebec, Canadá, H3T 1M5
- Retirado
- Research Site
-
Rimouski, Quebec, Canadá, G5L 5T1
- Recrutamento
- Research Site
-
Trois-Rivières, Quebec, Canadá, G8Z 3R9
- Recrutamento
- Research Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canadá, S7N 4H4
- Recrutamento
- Research Site
-
-
-
-
-
Beijing, China, 100142
- Recrutamento
- Research Site
-
Beijing, China, 101149
- Recrutamento
- Research Site
-
Changchun, China, 130000
- Recrutamento
- Research Site
-
Changsha, China, 410013
- Recrutamento
- Research Site
-
Chengdu, China, 610000
- Recrutamento
- Research Site
-
Chengdu, China, 610041
- Recrutamento
- Research Site
-
Chongqing, China, 400030
- Recrutamento
- Research Site
-
Fuzhou, China, 350014
- Recrutamento
- Research Site
-
Guangzhou, China, 510080
- Recrutamento
- Research Site
-
Hangzhou, China, 310006
- Recrutamento
- Research Site
-
Hangzhou, China, 310022
- Recrutamento
- Research Site
-
Hangzhou, China, 310016
- Recrutamento
- Research Site
-
Harbin, China, 150049
- Recrutamento
- Research Site
-
Hefei, China, 230601
- Recrutamento
- Research Site
-
Hefei, China, 230031
- Retirado
- Research Site
-
Jinan, China, 250117
- Recrutamento
- Research Site
-
Jining, China, 272011
- Retirado
- Research Site
-
Kunming, China, 650118
- Recrutamento
- Research Site
-
Lanzhou, China, 730000
- Recrutamento
- Research Site
-
Linhai, China, 317000
- Recrutamento
- Research Site
-
Linyi, China, 276001
- Recrutamento
- Research Site
-
Nanjing, China, 210009
- Recrutamento
- Research Site
-
Nanning, China, 530021
- Recrutamento
- Research Site
-
Nanning, China, 530000
- Recrutamento
- Research Site
-
Shanghai, China, 200032
- Recrutamento
- Research Site
-
Shanghai, China, 200030
- Recrutamento
- Research Site
-
Shanghai, China, 200433
- Recrutamento
- Research Site
-
Shenyang, China, 110022
- Recrutamento
- Research Site
-
Taiyuan, China, 030000
- Recrutamento
- Research Site
-
Tianjin, China, 300060
- Recrutamento
- Research Site
-
Wenzhou, China, 325000
- Recrutamento
- Research Site
-
Wuhan, China, 430022
- Recrutamento
- Research Site
-
Wuhan, China, 430030
- Recrutamento
- Research Site
-
Wuhan, China, 430010
- Recrutamento
- Research Site
-
Wuhan, China, 430000
- Recrutamento
- Research Site
-
Xi'an, China, 710061
- Recrutamento
- Research Site
-
Yangzhou, China, 225001
- Recrutamento
- Research Site
-
Zhengzhou, China, 450000
- Recrutamento
- Research Site
-
Zhengzhou, China, 450008
- Recrutamento
- Research Site
-
-
-
-
-
Changwon, Coréia do Sul, 51353
- Recrutamento
- Research Site
-
Incheon, Coréia do Sul, 21565
- Recrutamento
- Research Site
-
Seongnam-si, Coréia do Sul, 13496
- Recrutamento
- Research Site
-
Seoul, Coréia do Sul, 03080
- Recrutamento
- Research Site
-
Seoul, Coréia do Sul, 03722
- Recrutamento
- Research Site
-
Seoul, Coréia do Sul, 08308
- Ainda não está recrutando
- Research Site
-
Seoul, Coréia do Sul, 06973
- Recrutamento
- Research Site
-
Suwon, Coréia do Sul, 16247
- Recrutamento
- Research Site
-
Suwon, Coréia do Sul, 16499
- Recrutamento
- Research Site
-
-
-
-
-
Alicante, Espanha, 03010
- Recrutamento
- Research Site
-
Barcelona, Espanha, 08036
- Recrutamento
- Research Site
-
Barcelona, Espanha, 08003
- Recrutamento
- Research Site
-
Barcelona, Espanha, 08041
- Ainda não está recrutando
- Research Site
-
Jerez de la Frontera, Espanha, 11407
- Recrutamento
- Research Site
-
Reus, Espanha, 43204
- Recrutamento
- Research Site
-
Salamanca, Espanha, 37007
- Retirado
- Research Site
-
-
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 99508
- Recrutamento
- Research Site
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85719
- Recrutamento
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- Recrutamento
- Research Site
-
Springdale, Arkansas, Estados Unidos, 72762
- Recrutamento
- Research Site
-
-
California
-
Anaheim, California, Estados Unidos, 92801
- Recrutamento
- Research Site
-
Beverly Hills, California, Estados Unidos, 90211
- Recrutamento
- Research Site
-
Fountain Valley, California, Estados Unidos, 92708
- Recrutamento
- Research Site
-
Newport Beach, California, Estados Unidos, 92663
- Suspenso
- Research Site
-
-
Florida
-
Clermont, Florida, Estados Unidos, 34711
- Recrutamento
- Research Site
-
Gainesville, Florida, Estados Unidos, 32608
- Recrutamento
- Research Site
-
Miami Beach, Florida, Estados Unidos, 33140
- Recrutamento
- Research Site
-
Orange City, Florida, Estados Unidos, 32763
- Recrutamento
- Research Site
-
Orlando, Florida, Estados Unidos, 32806
- Recrutamento
- Research Site
-
Orlando, Florida, Estados Unidos, 32827
- Retirado
- Research Site
-
West Palm Beach, Florida, Estados Unidos, 33401
- Recrutamento
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Recrutamento
- Research Site
-
Atlanta, Georgia, Estados Unidos, 30318
- Recrutamento
- Research Site
-
Atlanta, Georgia, Estados Unidos, 30342
- Retirado
- Research Site
-
Atlanta, Georgia, Estados Unidos, 30303
- Suspenso
- Research Site
-
-
Illinois
-
Hinsdale, Illinois, Estados Unidos, 60521
- Recrutamento
- Research Site
-
-
Indiana
-
Noblesville, Indiana, Estados Unidos, 46062
- Recrutamento
- Research Site
-
-
Kentucky
-
Paducah, Kentucky, Estados Unidos, 42003
- Recrutamento
- Research Site
-
-
Maryland
-
Annapolis, Maryland, Estados Unidos, 21401
- Recrutamento
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Recrutamento
- Research Site
-
Boston, Massachusetts, Estados Unidos, 02114
- Recrutamento
- Research Site
-
-
Michigan
-
Dearborn, Michigan, Estados Unidos, 48126
- Recrutamento
- Research Site
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Recrutamento
- Research Site
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Recrutamento
- Research Site
-
Traverse City, Michigan, Estados Unidos, 49684
- Retirado
- Research Site
-
-
Mississippi
-
Hattiesburg, Mississippi, Estados Unidos, 39401
- Recrutamento
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64132
- Recrutamento
- Research Site
-
-
Montana
-
Bozeman, Montana, Estados Unidos, 59715
- Retirado
- Research Site
-
-
Nebraska
-
Grand Island, Nebraska, Estados Unidos, 68803
- Recrutamento
- Research Site
-
Omaha, Nebraska, Estados Unidos, 68130
- Recrutamento
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89102
- Recrutamento
- Research Site
-
Reno, Nevada, Estados Unidos, 89502
- Retirado
- Research Site
-
-
New Jersey
-
Voorhees Township, New Jersey, Estados Unidos, 08043
- Suspenso
- Research Site
-
-
New York
-
Stony Brook, New York, Estados Unidos, 11794
- Recrutamento
- Research Site
-
-
North Carolina
-
Greenville, North Carolina, Estados Unidos, 27834
- Recrutamento
- Research Site
-
Salisbury, North Carolina, Estados Unidos, 28144
- Recrutamento
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- Recrutamento
- Research Site
-
Columbus, Ohio, Estados Unidos, 43210
- Retirado
- Research Site
-
Maumee, Ohio, Estados Unidos, 43537
- Recrutamento
- Research Site
-
Toledo, Ohio, Estados Unidos, 43623
- Recrutamento
- Research Site
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97213
- Retirado
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, Estados Unidos, 29607
- Recrutamento
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57105
- Recrutamento
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, Estados Unidos, 37404
- Retirado
- Research Site
-
Knoxville, Tennessee, Estados Unidos, 37920
- Retirado
- Research Site
-
-
Texas
-
Fort Worth, Texas, Estados Unidos, 76104
- Recrutamento
- Research Site
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Research Site
-
Houston, Texas, Estados Unidos, 77030
- Retirado
- Research Site
-
Houston, Texas, Estados Unidos, 77090
- Suspenso
- Research Site
-
Kingwood, Texas, Estados Unidos, 77339
- Recrutamento
- Research Site
-
Odessa, Texas, Estados Unidos, 79761
- Recrutamento
- Research Site
-
-
Virginia
-
Fort Belvoir, Virginia, Estados Unidos, 22060
- Recrutamento
- Research Site
-
Leesburg, Virginia, Estados Unidos, 20176
- Recrutamento
- Research Site
-
Midlothian, Virginia, Estados Unidos, 23114
- Recrutamento
- Research Site
-
Richmond, Virginia, Estados Unidos, 23230
- Recrutamento
- Research Site
-
-
Washington
-
Tacoma, Washington, Estados Unidos, 98405
- Recrutamento
- Research Site
-
Vancouver, Washington, Estados Unidos, 98684
- Recrutamento
- Research Site
-
Wenatchee, Washington, Estados Unidos, 98801
- Recrutamento
- Research Site
-
-
Wisconsin
-
Appleton, Wisconsin, Estados Unidos, 54911
- Recrutamento
- Research Site
-
-
-
-
-
Budapest, Hungria, 1121
- Recrutamento
- Research Site
-
Edelény, Hungria, 3780
- Ainda não está recrutando
- Research Site
-
Gyula, Hungria, 5700
- Suspenso
- Research Site
-
Gyöngyös, Hungria, 3200
- Retirado
- Research Site
-
Gyöngyös - Mátraháza, Hungria, 3200
- Recrutamento
- Research Site
-
Győr, Hungria, 9024
- Recrutamento
- Research Site
-
Kecskemét, Hungria, 6000
- Recrutamento
- Research Site
-
Salgótarján, Hungria, 3100
- Retirado
- Research Site
-
Szekszárd, Hungria, 7100
- Recrutamento
- Research Site
-
Szolnok, Hungria, 5000
- Retirado
- Research Site
-
Székesfehérvár, Hungria, 8000
- Retirado
- Research Site
-
Törökbálint, Hungria, 2045
- Recrutamento
- Research Site
-
-
-
-
-
Bergamo, Itália, 24125
- Recrutamento
- Research Site
-
Genoa, Itália, 16132
- Recrutamento
- Research Site
-
Milan, Itália, 20141
- Recrutamento
- Research Site
-
Milan, Itália, 20162
- Recrutamento
- Research Site
-
Monza, Itália, 20052
- Recrutamento
- Research Site
-
Padova, Itália, 35128
- Recrutamento
- Research Site
-
Pavia, Itália, 27100
- Recrutamento
- Research Site
-
Ravenna, Itália, 48100
- Recrutamento
- Research Site
-
Roma, Itália, 00128
- Recrutamento
- Research Site
-
Rozzano, Itália, 20089
- Recrutamento
- Research Site
-
-
-
-
-
Bunkyō City, Japão, 113-8431
- Recrutamento
- Research Site
-
Bunkyō City, Japão, 160-0023
- Recrutamento
- Research Site
-
Fukuoka, Japão, 812-8582
- Recrutamento
- Research Site
-
Fukuoka, Japão, 814-0180
- Recrutamento
- Research Site
-
Hakodate-shi, Japão, 040-8611
- Recrutamento
- Research Site
-
Hidaka-shi, Japão, 350-1298
- Recrutamento
- Research Site
-
Hirakata-shi, Japão, 573-1191
- Recrutamento
- Research Site
-
Hirosaki-shi, Japão, 036-8563
- Recrutamento
- Research Site
-
Hiroshima, Japão, 730-8518
- Recrutamento
- Research Site
-
Kanazawa, Japão, 920-8641
- Recrutamento
- Research Site
-
Kashiwa, Japão, 227-8577
- Recrutamento
- Research Site
-
Kawasaki-shi, Japão, 216-8511
- Recrutamento
- Research Site
-
Kumamoto, Japão, 860-8556
- Recrutamento
- Research Site
-
Matsusaka-shi, Japão, 515-8544
- Recrutamento
- Research Site
-
Matsuyama, Japão, 790-0024
- Recrutamento
- Research Site
-
Nagoya, Japão, 460-0001
- Recrutamento
- Research Site
-
Niigata, Japão, 951-8566
- Recrutamento
- Research Site
-
Okayama, Japão, 700-8558
- Recrutamento
- Research Site
-
Osaka, Japão, 545-8586
- Retirado
- Research Site
-
Osakasayama-shi, Japão, 589-8511
- Recrutamento
- Research Site
-
Sagamihara-shi, Japão, 252-0375
- Recrutamento
- Research Site
-
Sapporo, Japão, 003-0804
- Recrutamento
- Research Site
-
Takaoka-shi, Japão, 933-8555
- Recrutamento
- Research Site
-
Takatsuki-shi, Japão, 569-8686
- Recrutamento
- Research Site
-
Tokushima, Japão, 770-8503
- Recrutamento
- Research Site
-
Tokyo, Japão, 104-0045
- Recrutamento
- Research Site
-
Utsunomiya, Japão, 320-0834
- Recrutamento
- Research Site
-
Yokohama, Japão, 221-0855
- Recrutamento
- Research Site
-
-
-
-
-
Olsztyn, Polônia, 10-357
- Recrutamento
- Research Site
-
Poznan, Polônia, 60-569
- Recrutamento
- Research Site
-
Przemyśl, Polônia, 37-700
- Recrutamento
- Research Site
-
Warsaw, Polônia, 02-781
- Recrutamento
- Research Site
-
Warsaw, Polônia, 01-138
- Recrutamento
- Research Site
-
-
-
-
-
San Juan, Porto Rico, 00909
- Recrutamento
- Research Site
-
-
-
-
-
Cheltenham, Reino Unido, GL53 7AN
- Suspenso
- Research Site
-
Inverness, Reino Unido, IV2 3UJ
- Suspenso
- Research Site
-
London, Reino Unido, SW17 0QT
- Recrutamento
- Research Site
-
London, Reino Unido, SW10 9NH
- Recrutamento
- Research Site
-
London, Reino Unido, SE1 9RT
- Retirado
- Research Site
-
Norwich, Reino Unido, NR4 7UY
- Recrutamento
- Research Site
-
Preston, Reino Unido, PR2 9HT
- Recrutamento
- Research Site
-
Truro, Reino Unido, TR1 3LJ
- Recrutamento
- Research Site
-
-
-
-
-
Bangkok, Tailândia, 10400
- Recrutamento
- Research Site
-
Bangkok, Tailândia, 10700
- Recrutamento
- Research Site
-
Hat Yai, Tailândia, 90110
- Recrutamento
- Research Site
-
Muang, Tailândia, 22000
- Recrutamento
- Research Site
-
Mueang, Tailândia, 20000
- Recrutamento
- Research Site
-
Mueang, Tailândia, 32000
- Recrutamento
- Research Site
-
-
-
-
-
Changhua, Taiwan, 500
- Ainda não está recrutando
- Research Site
-
Kaohsiung City, Taiwan, 80756
- Recrutamento
- Research Site
-
New Taipei City, Taiwan, 220
- Recrutamento
- Research Site
-
Taichung, Taiwan, 40447
- Recrutamento
- Research Site
-
Taichung, Taiwan, 40705
- Recrutamento
- Research Site
-
Tainan, Taiwan, 704
- Recrutamento
- Research Site
-
Taipei, Taiwan, TAIWAN
- Recrutamento
- Research Site
-
Taipei, Taiwan, 10002
- Recrutamento
- Research Site
-
Taipei, Taiwan, 112
- Recrutamento
- Research Site
-
Taipei, Taiwan, 0116
- Recrutamento
- Research Site
-
Taoyuan, Taiwan, 333
- Recrutamento
- Research Site
-
-
-
-
-
Adapazarı, Turquia (Türkiye), 54100
- Recrutamento
- Research Site
-
Ankara, Turquia (Türkiye), 6200
- Recrutamento
- Research Site
-
Ankara, Turquia (Türkiye), 06560
- Recrutamento
- Research Site
-
Antalya, Turquia (Türkiye), 07070
- Recrutamento
- Research Site
-
Diyarbakır, Turquia (Türkiye), 21280
- Recrutamento
- Research Site
-
Istanbul, Turquia (Türkiye), 34030
- Recrutamento
- Research Site
-
Istanbul, Turquia (Türkiye), 34890
- Recrutamento
- Research Site
-
-
-
-
-
Da Nang, Vietnã, 550000
- Recrutamento
- Research Site
-
Hanoi, Vietnã, 100000
- Recrutamento
- Research Site
-
Ho Chi Minh City, Vietnã, 700000
- Recrutamento
- Research Site
-
Ho Chi Minh City, Vietnã, 700000
- Retirado
- Research Site
-
Huế, Vietnã, 530000
- Retirado
- Research Site
-
Hà Nội, Vietnã, 100000
- Recrutamento
- Research Site
-
Vinh, Vietnã, 460000
- Retirado
- Research Site
-
Vĩnh Yên, Vietnã, 280000
- Recrutamento
- Research Site
-
-
-
-
-
Innsbruck, Áustria, 6020
- Recrutamento
- Research Site
-
Krems, Áustria, 3500
- Recrutamento
- Research Site
-
Linz, Áustria, 4020
- Recrutamento
- Research Site
-
Rankweil, Áustria, 6830
- Recrutamento
- Research Site
-
Vienna, Áustria, 1210
- Recrutamento
- Research Site
-
Vienna, Áustria, 1140
- Recrutamento
- Research Site
-
Wels, Áustria, 4600
- Retirado
- Research Site
-
-
-
-
-
Chennai, Índia, 600031
- Recrutamento
- Research Site
-
Dwārka, Índia, 110075
- Recrutamento
- Research Site
-
Jaipur, Índia, 302004
- Recrutamento
- Research Site
-
Kolkata, Índia, 700099
- Recrutamento
- Research Site
-
Marg Jaipur, Índia, 302004
- Retirado
- Research Site
-
Nagpur, Índia, 440001
- Recrutamento
- Research Site
-
Nashik, Índia, 422011
- Recrutamento
- Research Site
-
New Delhi, Índia, 11029
- Recrutamento
- Research Site
-
New Delhi, Índia, 110085
- Recrutamento
- Research Site
-
Surat, Índia, 395002
- Recrutamento
- Research Site
-
Thiruvananthapuram, Índia, 695011
- Retirado
- Research Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Histologically or cytologically documented non-squamous NSCLC.
- Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation.
- Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved and available targeted first-line therapies.
- Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers.
- Known tumour PD-L1 expression status defined as TC ≥ 50%
- At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline
- ECOG performance status of 0 or 1
- Adequate bone marrow reserve and organ function
Exclusion Criteria:
- Prior systemic therapy for advanced/metastatic NSCLC.
- Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant.
- History of another primary malignancy within 3 years
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Any evidence of severe or uncontrolled disease that makes it undesirable for the participant to participate in the study or that would jeopardies compliance with the protocol.
- Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage.
- History of any ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, has current or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- Has significant pulmonary function compromise, as determined by the investigator
- Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants.
- History of leptomeningeal carcinomatosis
- Known clinically significant corneal disease
- Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled
- History of active primary immunodeficiency
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm 1: Datopotamab Deruxtecan in Combination With Rilvegostomig
Participants in the Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig group will receive Dato-DXd plus rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Datopotamab Deruxtecan IV (intravenous)
Outros nomes:
Rilvegostomig IV (intravenous)
Outros nomes:
|
|
Experimental: Arm 2: Rilvegostomig Monotherapy
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Rilvegostomig IV (intravenous)
Outros nomes:
|
|
Comparador Ativo: Arm 3: Pembrolizumab Monotherapy
Participants in the pembrolizumab group will receive pembrolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Pembrolizumab IV (intravenous)
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-Free Survival (PFS) in TROP2 biomarker positive participants.
Prazo: Approximately 4 years
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Overall Survival (OS) in TROP2 biomarker positive participants.
Prazo: Approximately 6 years
|
OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of OS. |
Approximately 6 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-Free Survival (PFS) in the FAS population.
Prazo: Approximately 4 years
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • FAS population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Overall Survival (OS) in the FAS population.
Prazo: Approximately 6 years
|
OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • FAS population The measure of interest is the HR of OS. |
Approximately 6 years
|
|
Assessment of Objective Response Rate (ORR) by BICR in TROP2 biomarker positive and FAS populations
Prazo: Approximately 4 years
|
ORR is defined as the proportion of participants who have a CR or PR, as determined by BICR per RECIST 1.1. The analyses will include all randomised participants, as randomised, with measurable disease at baseline, in the following populations:
The measure of interest is the difference of the ORR. ORR by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Assessment of Duration of Response (DoR) by BICR in TROP2 biomarker positive and FAS populations
Prazo: Approximately 4 years
|
DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR or death due to any cause. The analyses will include all randomised participants who have a response, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following populations:
|
Approximately 4 years
|
|
Participant-reported lung cancer symptoms of NSCLC and participant-reported GHS/QOL in participants treated with Dato-DXd in combination with rilvegostomig relative to pembrolizumab.
Prazo: Approximately 6 years
|
Time to deterioration in: pulmonary symptoms (dyspnoea, cough, and chest pain) as measured by the NSCLC-SAQ, in overall lung cancer symptoms as measured by the NSCLC-SAQ, and in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:
|
Approximately 6 years
|
|
Participant-reported physical functioning in participants treated with Dato DXd in combination with rilvegostomig relative to pembrolizumab.
Prazo: Approximately 6 years
|
Time to deterioration in physical functioning as measured by PROMIS Physical Function short form 8c. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:
|
Approximately 6 years
|
|
Pharmacokinetics (PK)
Prazo: Approximately 6 years
|
Concentration of rilvegostomig, Dato-DXd, total anti TROP2 antibody, and MAAA 1181a (payload deruxtecan) in plasma or serum and PK parameters (peak and trough concentrations). |
Approximately 6 years
|
|
Immunogenicity
Prazo: Approximately 6 years
|
Presence of ADA for Dato-DXd and rilvegostomig (confirmatory results, titres and neutralising antibodies for confirmed positive samples). |
Approximately 6 years
|
|
Second Progression-Free Survival (PFS2).
Prazo: Approximately 6 years
|
PFS2 is defined as the time from randomisation to the earliest of the progression events (following the initial progression), subsequent to first subsequent therapy, or death. Progression event includes radiological (RECIST 1.1) or clinical disease progression. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard practice. The analyses will include all randomised participants, as randomised, regardless of whether the participant withdraws from subsequent therapy and regardless of missed visits, in the following populations:
|
Approximately 6 years
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Safety of Dato-DXd in combination with rilvegostomig and rilvegostomig monotherapy as compared with pembrolizumab.
Prazo: Approximately 6 years
|
Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE Version 5.0). |
Approximately 6 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Suresh S. Ramalingam, MD, Emory University, Atlanta, Georgia, United States of America.
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- D7632C00001
- 2023-505077-32-00 (Identificador de registro: CTIS (EU))
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Prazo de Compartilhamento de IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Critérios de acesso de compartilhamento IPD
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool .
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .